MEDA seeks marketing authorization for Zyclara in Europe

NewsGuard 100/100 Score
Jun 23 2011

“Zyclara will strengthen Meda's dermatology franchise in Europe. We look forward to provide AK patients with a new product that can treat larger areas of the skin”

MEDA: The marketing authorization application for the patented product Zyclara (imiquimod 3.75% cream) has been filed with the European Medicines Agency (EMA). Zyclara has been documented for once-daily topical treatment of actinic keratosis (AK).

Zyclara expands the treatment area to the full face or balding scalp and could become a first line therapy for AK. More than 1,400 patients have been included in seven clinical studies.

"Zyclara will strengthen Meda's dermatology franchise in Europe. We look forward to provide AK patients with a new product that can treat larger areas of the skin", says Anders Lönner, CEO of Meda.

Source:

MEDA AB

Posted in: Medical Condition News | Pharmaceutical News

Tags: , ,

Comments (0)

Suggested Reading

Clinique and Mount Sinai partner to establish the Mount Sinai-Clinique Healthy Skin Dermatology Center
Study reveals skin bacteria removal boosts brain attention signals
Towards better diagnosis of neurodegenerative disorders: Skin biopsy for α-synuclein detection proves effective
New study finds interferon-γ release assays more effective than skin tests in predicting tuberculosis
Childhood obesity not linked to adult skin cancer risk, study says
Current AI programs do worse at identifying skin lesions in people of color, research shows
Teledermatology study exposes skin tone diagnosis gaps, AI offers improvement
Greenspace exposure boosts gut and skin microbiota health, study finds

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Reversing time: Hyaluronic acid injections offer lasting improvement in aging skin